The evaluation of human specific immunotherapeutics is hampered by a lack of preclinical oncology models which feature a functional human immune system. With the progression of humanization protocols, it has become possible to successfully reconstitute functional human immunity in mice. These humanized mice can be combined with human cancer cell lines or patient-derived xenograft (PDX) models for the assessment of agents on human tumors within human immunity.
To unlock the full potential of these complex models a clear understanding of the humanization process, and of the features and limitations of humanized mice platforms, is required. In this webinar, Dr. Thatte reviews currently available humanized models and will discuss the application of each model to preclinical immuno-oncology drug development.
Dr. Jayant Thatte, Crown Bioscience, is an immunologist with 20 years of post-PhD research experience in academia and industry in the areas of cancer, autoimmunity, inflammation, and pain. Dr. Thatte completed his PhD at the National Institute of Immunology in New Delhi, India, followed by post-doctoral research at UT Southwestern Medical Center at Dallas and the University of Virginia at Charlottesville.
Prior to joining Crown Bioscience, Dr. Thatte successfully progressed two drug discovery programs to clinical development at Arena Pharmaceuticals.
As General Manager at Crown Bioscience, Jayant leads the development of several platforms including PDX models, syngeneic, and humanized PDX platforms to support immuno-oncology projects for clients.